David Tierney

Icon Bioscience, Inc. develops and markets ophthalmic pharmaceuticals. It develops specialty pharmaceuticals targeting ophthalmic indications including macular edema, glaucoma, age-related macular degeneration and cataract surgery. The firm's pipeline includes IBI-10090, IBI-20089, IBI-60089, and IBI-80090. The company was founded by Vernon G. Wong and is headquartered in Newark, CA.

Viatar CTC Solutions, Inc. is a medical technology company, which engages in the treatment of patients with metastatic cancer. Its products include Viatar Therapeutic Oncopheresis System that removes circulating tumor cells from whole blood using label-free cross-flow filtration. The company was founded by Ilan K. Reich on December 18, 2007 and is headquartered in Lowell, MA.

Bimeda, Inc. manufactures veterinary pharmaceuticals and animal health care products. The company has operations in the United Kingdom, Canada, the United States, Mexico, and Ireland. The firm was founded in 1997 and is headquartered in Oakbrook, IL

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

BioPharmX Corp. is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. The HyantX delivery system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Campbell, CA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.